longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Neogenomics

NEO

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -46.90, below the reasonable range, cheaper than 94.86% of the time in the past 5 years, and the industry ranks 58/74, the industry Median --.

-46.9xP/E
$18.94Stock price
$-0.40Earnings per share
-46.9xP/E
Stock price$18.94Earnings per share$-0.40

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-16.03x
Typical range
-25.37x–-9.79x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
07142128

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x40x80x120x160x200x
P/E ratio
Name/Symbol
GHUSGuardant Health
-51.76x2.92%$23.47B
HIMSUSHims & Hers Health
-46.00x209.86%$6.53B
RDNTUSRadnet
-282.42x128.00%$5.96B
WGSUSGeneDx
-27.32x359.59%$2.91B
NEOUSNeogenomics
-46.90x64.73%$2.43B
AGLUSagilon health
-6.48x93.07%$1.51B
INNVUSInnovage
-583.56x2,301.70%$1.48B
OPKUSOpko Health
-16.48x25.44%$1.20B
LMRIUSLumexa Imaging
-40.36x146.66%$1.12B
CSTLUSCastle Biosciences
-55.83x53.28%$1.08B
GMRSUSGMR Solutions
-9.26x91.45%$700.66M
FLGTUSFulgent Genetics
-7.05x42.64%$595.16M
PREUSPrenetics Global
-8.03x19.04%$377.50M
AONCUSAmerican Oncology Network
----$371.06M
BDSXUSBiodesix
-10.85x42.77%$301.34M
GAMGUSGlobal Asset Management Group, Inc.
-389.83x--$220.03M
AIRSUSAirSculpt Tech
-12.93x33.33%$151.76M
NAKAUSNakamoto
-0.35x101.83%$146.74M
CORBFUSGlobal Cord Blood Corporation
----$127.35M
PARKUSPark Dental Partners
-27.37x--$96.77M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.